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Abstract
A relationship between hypertension and repression has long been observed in the
psychological literature. Those who ex�ibit repressive coping styles also tend to exhibit
elevated blood pressure levels. Classically, this relationship has been explained by
emphasizing the role of repression in elevating, through unknown mechanisms, blood
pressure. Recent research, however, suggests that the directionality of this relationship
may be reversed, and high blood pressure, through baroreceptor-mediated, endogenous
opioid activity, may result in repressive phenomena. The present study tests this
hypothesis by comparing the disclosure of 8 normotensives and 10 hypertensives after
receiving either the opioid antagonist naltrexone or a placebo. Administration of the drug
or placebo was double-blind and randomized across 4 laboratory visits. Following
absorption of the drug, participants verbally described their mood, conflicts, stressors,
and concerns. Following the verbal narrative, participants completed measures of
repressive coping style, disclosure, mood, and self-perceptions. To accommodate for the
small sample size, planned comparisons were used for analyses. Specifically, the
hypothesis was tested that naltrexone would significantly alter dependent measures, in the
direction of higher disclosure and less repression, in hypertensive subjects only. Results
supported the hypothesis. Significantly greater disclosure and significantly less repression
were exhibited by hypertensives in the drug sessions versus placebo sessions. The drug
condition had no effect on the self-report of normotensives. The results provide initial
evidence for the role of endogenous opioids in repression and hypertension.
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CHAPTER I: INTRODUCTION
A link between the psychological concept of repression and the physiological
condition of hypertension is well described in the psychosomatic literature. These two
phenomena have been found to be positively correlated, with those showing signs of
repression also exhibiting elevated blood pressure or hypertension. This relationship has
been a key example in the academic problem of the mind/body relationship and the
apparent correlation between repression and hypertension has been a central argument for
the notion of psychosomatic illness and the idea that complex psychical processes can
have concrete, physical consequences.
The relationship between repression and hypertension has been strongly
supported by the scientific literature. A number of correlational studies have found an
inverse relationship between self-reported stressors and hypertension. In one study,
Winkleby, Ragland, and Syme ( 1988) conducted a comprehensive health exam on 1,428
San Francisco bus drivers. In addition to self-report stress scales, measures of blood
pressure (as part of a physical exam) were included. The authors found a significant,
inverse relationship between the bus drivers' blood pressures, as measured in the
checkup, and their self-reported, daily stressors. Bus drivers with the highest blood
pressure levels were least likely to report current stress. This inverse relationship has
been found in many other studies as well. Rose, Jenkins, and Hurst ( 1978) found that
hypertensive air traffic controllers reported significantly fewer life-change events, as
compared to their normotensive coworkers. Harburg and colleagues ( 1970) found that
hypertensive members of inner-city Detroit communities reported their environment as
less dangerous than did normotensives in the same communities. Similarly, Tibblin &
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Lindstrom (1972) found that hypertensives reported fewer health symptoms and that
degree of hypertension was negatively correlated with symptom reporting.
The results of these studies are most striking in how they differ from the rather
large body of evidence suggesting a positive relationship between stressors and blood
pressure. Environmental stressors have been linked to elevated blood pressure in a variety
of situations and populations, including catastrophic disasters (Baum, 1990), dangerous
Iiving areas (Rofe & Goldberg, 1983), job loss (Kasi & Cobb, 1970), and job strain
(Theorell et al., 1991; Fox, Dwyer, & Ganster, 1993; Schaubroeck & Ganster, 1993). A
meta-analytic review of psychosocial stressors and hypertension/elevated blood pressure
concluded that the difference could be accounted for by objective versus subjective
measures of stress (Nyklicek, Vingerhoets, & Van Heck, 1996). When objective indices
of stress were used (e.g., laboratory stressor, high-risk job, or residence in a dangerous
neighborhood), a strong positive correlation between stress and blood pressure can be
seen. This relationship, however, is non-existent or even inverted when self-report scales
are used as a measure of stress. This discrepancy between self-report and objective
measures of stress and their relationship to blood pressure is hypothesized to be the result
of an altered basis of stress appraisal exhibited by hypertensives (Nyklicek, Vingerhoets,
& Van Heck, 1996; Winkleby, Ragland, & Syme, 1988). Hypertensives neither

acknowledge nor disclose stress to the degree that normotensives do.
Evidence of an altered basis of perception in hypertensives was offered by Sapira,
Scheib, Moriarty & Shapiro (1971). In their study, normotensive and hypertensive
individuals were shown two movies: one of a "good doctor" interacting with a patient and
one of a "bad doctor," who was very rude with the patient in the film. Hypertensive
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individuals, who exhibited greater mean arterial pressure responses to the films, were
nevertheless much more likely than normotensives to report seeing no differences in the
behavior of the two doctors.
Hypertensives also report fewer life events and less emotional reaction to those
life events. Svensson and Theorell (1983) found that hypertensives exhibiting consistent
vasoconstriction (but not other hypertensives) reported fewer life events and less
emotional reaction, when compared to normotensive and hypotensive groups. Similar
results have been found in longitudinal studies. Theorell, Svensson, and Waller (1986)
measured the blood pressure of 106 men at age 18. Ten years later, those subjects who
had earlier exhibited early stage (and asymptomatic) hypertension reported significantly
fewer life events than the other subjects. The diminished reporting exhibited by
hypertensives also extends to self-reported neurotic symptoms (Davies, 1970) as well as
self-reported cold-pressor (McCubbin & Bruehl, 1994), finger-pressure (Bruehl, ·carlson,
and McCubbin, 1992) and thermal (Sheps, Bragdon, Gray, Ballenger, Usedom, &
Maixner, 1992) pain.
Zamir and Shuber (1980) tested the relationship between blood pressure and the
experience of pain in hypertensive and normotensive individuals. Electrical stimulation
of tooth pulp was gradually increased until the subject reported being in pain.
Hypertensive status significantly predicted reported pain threshold in three separate age
groups. In each case, hypertensives withstood almost double the voltage of the
normotensive group. Furthermore, there were significant positive relationships between
blood pressure (systolic and diastolic) and pain threshold in all groups. Increased
tolerance to pain has also been found in adolescent boys with subclinical elevations in
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resting systolic blood pressure, suggesting that the inverse blood pressure/pain reporting
relationship begins before the onset of hypertension (Ditto, Seguin, Boulerice, Pihl. &
Tremblay, 1998). Laboratory studies have also found that the reduced self-report of pain
can be extended to psychosocial stress as well (Nykilcek, Vingerhoets, & Van Heck,
2001).
While hypertensives have been found to exhibit repression-like behaviors,
attempts to measure repression, per se, has proven difficult. Most early laboratory work
on repression was criticized as being poorly defined or too far removed from the
repression encountered by psychotherapists (Davis & Schwartz, 1987). Objective
measures of a repressive coping style� however, served as a catalyst for much of the
laboratory work on repression. Byrne (1 961 ) produced the Byrne Repression
Sensitization (R-S) scale to differentiate the two coping styles. More recently, however,
Weinberger and others have proposed a measure of repressive coping style that crosses
two existing scales: anxiety and defensiveness (Weinberger, Schwartz, & Davidson,
1979). Those exhibiting the "repressive copi�g style" score low on state anxiety (as
measured, for example, by the Taylor Manifest Anxiety Scale; Taylor, 1953) but high on
defensiveness, as measured by the Marlowe-Crowne Scale of Social Desirability
(Crowne & Marlowe, 1960). Repressive copers are, therefore, those who claim low
anxiety but score high on defensiveness, indicating that they may have a tendency to
underreport negative experiences.
Research utilizing this method of identifying repressors has been fruitful, with
many studies showing that repressive groups exhibit physiological stress responses
greater than either true high anxious or true low anxious groups (Aspendorf & Scherer,
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1983; Weinberger, 1990). Furthermore, defensiveness (measured by the MarloweCrowne Scale) has been found to be strongly associated with hypertension, regardless of
high or low anxiety scores (Mann & James, 1998).
A review of psychosocial variables and hypertension found support for a
repression/hypertension link (Sommers-Flanagan & Greenberg, 1989). Of nine studies
looking at repression-type variables, six found a significant relationship between
repression and hypertension. The wide range of scales used to measure "repression"
make results difficult to compare, however. The Thematic Apperception Test, MMPI
Alexithymia Scale, Byrne's Repression-Sensitization Scale, Crowne-Marlowe Social
Desirability Scale, and General Well-Being Questionnaire were all used to measure
denial of negative affect or neuroticism.
Previous research, therefore, supports the notion that repression and hypertension
are closely related. Increases in blood pressure are associated with diminished negative
self-report. Individuals with hypertension or elevated blood pressure report less pain,
stress, neurotic symptoms, and negative affect than do normotensives. The next step,
then, after determining the existence of a relationship, is to ascertain the directionality of
that relationship.
The classic view of psyche-soma issues was put forth by early clinicians and
psychoanalysts who believed that repression acted as the causal variable. One of the
earliest recorded suggestions of a casual relationship between psyche and soma was
offered by a tenth century physician, who believed that repressed hostility was a direct
cause of rheumatoid arthritis (Shafii, 1973; as cited in McMahon, 1976). It was Freud and
Breuer, however, who clarified and popularized the first unidirectional model of
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psychosomatic phenomena. In their ( 1893/1966) hydraulic model of emotional
functioning, traumatic events result in excess psychic energy that must be released. If this
energy is not released, it will accumulate and eventually find another form of expression,
either through physical or psychological symptoms (Smyth and Greenberg, 2000). Many
current theorists and clinicians still maintain that distress, when not allowed to manifest
psychically, finds a somatic route of expression (McDougall, 1989).
The greatest problem with the early model of disease as physical expression of
psychological distress lies perhaps in the inability of the theory to fit known
physiological and neurological mechanisms. There are no known physiological systems
that support the idea that dammed up emotional energy can find a route of expression
through the body and thus cause physical disease. There are no convincing biological,
physiological, or neurological models which explain 1) the physical form of this energy,
2) how the energy is blocked or 3) how psychical energy transmutes to a physical one.
Partially in response to these problems, modem psychodynamic theory has
replaced the hydraulic model with a different hypothesis: the effort required to maintain
psychological repression (i.e., to actively keep offending material out of conscious
awareness) puts a constant strain on the physiological system. Overactivation of the
physical body is necessary to provide the energy required to maintain this psychological
dissociation (Esterling, Antoni, Kumar & Schneiderman, 1990). With this approach, there
is no need to hypothesize possible points where bad psychical energy is transmuted into
bad physical energy. Repression can be described as simply another cognitive/mental
process that requires energy. The current psychodynamic view of psychosomatic
phenomena is captured by Shedler, Mayman, and Manis ( 1993), who state,
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"Psychological defense has physiological costs. It is associated with autonomic reactivity
and may be a risk factor for medical illness."
Since blood pressure is closely tied with activation of the sympathetic nervous
system, which provides and mobilizes energy for most behavior, its place in the
"physiological cost" hypothesis can be described thusly: chronically elevated blood
pressure levels are the result of resources being constantly utilized for the maintenance of
repression. Because the anxiety-provoking thoughts can never be allowed to enter
consciousness, the demand on the cardiovascular system is constant. Hypertension, then,
is simply the manifestation of the sympathetic system being constantly overworked in
order to fuel the active and ongoing repression.
Very little evidence, however, exists for this view of repression as the causal
variable in the repression/hypertension relationship. Much of the support comes from
case studies in which a drop in blood pressure was observed after the disclosure of some
traumatic event (Mann and Delon, 1995). These studies are usually problematic,
however, in that the frequency of cardiovascular measurement is not sufficient to clearly
determine whether the drop in blood pressure or the reduction of repression came first.
Limited evidence for the repression-causes-hypertension model can be found in
the small but suggestive emotional suppression literature. In these studies, emotional
suppression (the conscious inhibition of one's own emotional expressive behavior) is
experimentally varied by instructing a group to show or not to show any emotion during a
lab stressor, regardless of their natural inclinations. In an early study by Gambaro and
Rabin ( 1969), greater blood pressure increases were induced in subjects who were not
allowed to express anger to an anger-arousing lab stressor. In a more recent experiment,
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Gross and Levenson (1993) instructed subjects to watch disgust-evoking films: one of a
burn victim treatment and another of an amputation procedure. After determining that
these films elicited strong feelings of disgust in viewers, the films were shown to a
nonsuppression group and a suppression group. The suppression group was instructed to
behave "in such a way that a person watching you would not know you were feeling
anything." In general, the suppression group demonstrated a significantly different
physiological response to the film in a way that suggested increased sympathetic arousal
(greater skin conductance, greater finger pulse amplitude, and shorter pulse transmission
times to the finger).
The study's usefulness to the present discussion, however, is limited by several
factors. First, blood pressure, which is a necessary variable for discussing hypertension,
was not measured in the Gross and Levenson (1993) study. Second, the only
cardiovascular measure related to blood pressure that was included in the study was heart
rate, and the suppression group exhibited greater deceleration as compared to the non
suppressing group. This finding runs counter to what would be expected if suppression
was causally linked to elevated blood pressure.
A more recent study (Harris, 2001) addressed one of the previous arguments by
including blood pressure in the physiological variable set. Participants were instructed to
sing "The Star Spangled Banner" in front of a video camera. Afterwards, each subject
watched the videotape of their singing with two confederates (this process was
demonstrated previously by the same author to produce strong feelings of
embarrassment). Similar to the Gross & Levenson (1993) study, one group was
instructed, before the confederates entered the room, not to display any emotion and to
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behave so that no one could guess what emotion they were experiencing. Results showed
that the suppression group demonstrated significantly higher systolic and diastolic blood
pressure as compared to the nonsuppression group. In addition to its inclusion of blood
pressure, this study is important because it measured emotional suppression in a live
interpersonal (albeit contrived) situation. This study shows that emotional inhibition can
have an impact on blood pressure.
Unfortunately, all these studies share a common limitation: that the experimental
group was given a task (to hide emotions) above and beyond that of the control group.
Increased blood pressure, then, may be due mainly to the anxiety of being evaluated or
the effort required to perform the task (Gross & Levenson, 1993). It is unknown,
therefore, whether or not suppression has any effect above and beyond that of any other
task in which the participant might be evaluated.
Furthermore, and more important to the present discussion, the authors in the
previous studies have made no attempt to link their findings to unconscious repressive
phenomena. With the available evidence, it seems more parsimonious to assume that
differences in suppression and nonsuppression groups exist as a natural function of a
conscious task. The results, therefore, should not be used to suggest that unconscious
repression of emotions results in similar cardiovascular reactivity.
As the last form of support, disclosure has been investigated as a factor in blood
pressure levels. If hypertension is a result of psychological repression, inhibition, or
suppression of traumatic events or anxiety-provoking conflict, then the release of
traumatic memories through disclosure should lead to a decrease in blood pressure. While
a number of studies have shown that disclosure leads to lower physician visits
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(Pennebaker & Beall, 1986; Greenberg & Stone, 1992) and increased immune function
(Pennebaker, Kiecolt-Glaser, & Glaser, 1988; Francis & Pennebaker, 1992; Esterling et
al., 1990), no study has found any reduction in blood pressure.
Pennebaker, Hughes, and O'Heeron (1987) investigated physiological differences
between high and low disclosure. Participants talked about two subjects: 1) a traumatic
experience and 2) what they were going to do after the experiment. Individuals were
categorized as either high or low disclosers based on judged depth of disclosure in their
spoken narratives. Following the traumatic-event narrative, SBP levels of low-disclosers
returned to baseline levels, while SBP levels of high-disclosers dropped to levels
significantly lower than baseline levels. These results were interpreted by the authors as
evidencing greater recovery facilitated by high disclosure.
Interpretation of the data is complicated, however, by a number of factors. First,
the main independent variable, disclosure, was an unassigned attribute variable.
Differences in physiology, therefore, may be due to trait correlates of a high tendency to
disclose. Second, high disclosers exhibited hisher DBP levels across all phases of the
experiment, including post-disclosure recovery. It is unclear why a discrepancy between
systolic and diastolic blood pressure was found. Third, if the act of disclosure leads· to
reduced blood pressure, we would expect post-traumatic levels to be lower than post
trivial levels, where little actual disclosure is taking place. Results show, however, that
there is virtually no difference i i:t blood pressure following traumatic-event disclosure and
trivial-event disclosure, suggesting that "disclosing" a trivial event may be just as healthy
as disclosing a traumatic one.
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Therefore, while the relationship between repression and hypertension has been
strongly supported by research, there is little evidence that repression acts as the causal
variable in this relationship. A much larger literature, however, supports the notion that
hypertension may actually result in repressive phenomena. Eisenbud ( 1939) was one of
the first researchers to state that hypertension may induce repression. Eisenbud
speculated that repression occurred as a consequence of sympathetic nervous activity and
was a dependent effect of sympathetic system chemicals on the brain.
Research on animals and humans has indeed supported this hypothesis. As
mentioned previously, in the classic psychosomatic position on the
repression/hypertension relationship, hypertension is a by-product of repression and that
repression is an attempt at avoiding anxiety or negative emotional material. Research in
the hypertension literature, however, suggests that the range of cognitive/psychological
impairment associated with hypertension extends well beyond emotional matters. Apter,
Halstead, and Heimburger ( 195 1) suggested that "impairment of cerebral functions
equivalent to that seen in patients with surgical removal of both frontal lobes may occur
early in the course of essential hypertension without neurological signs" (p. 8 12; as cited
in Madden and Blumenthal, 1989). A review by Waldstein, Manuck, Ryan, & Muldoon
( 199 1) gathered evidence that". . . hypertensives are found to perform more poorly than
normotensives, particularly on tests of memory, attention, and abstract reasoning, and
less consistently on tests of perception, constructional ability, mental flexibility, and
psychomotor speed" (p. 45 1).
Relationships between hypertension and memory have also been described in the
literature. Hypertension has been found to be associated with poorer functioning in verbal
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memory (Franceschi, Tancredi, Smirne, Mercinelli, & Canal 1982; Mazzucchi, Mutti,
Poletti, Ravanetti, Novarini & Parma, 1986; Schmidt, Fazekas, Offenbacher, Lytwyn,
Blematl, Niederkorn, Homer, Payer, & Friedl, 199 1; Waldstein, Manuck, Ryan, &
Muldoon, 199 1), visual memory (Franceshi et al. , 1982; Mazzucchi et al., 1986;
Waldstein et al., 199 1; Waldstein, Ryan, Manuck, Parkinson, & Bromet, 199 1), and
tactile memory (Elias, Robbins, Schultz, Streeten & Elias 1987; Pentz, Elias, Wood,
Schultz, & Dineen, 1979). These results are important because they show that
inaccessibility of emotional material is not unique in its relationship to hypertension.
There is, therefore, no reason to award repression a special place in causing hypertension,
as it may be just one of many mental phenomena associated with hypertension.
The causative role of hypertension in cognitive deficiencies involving memory
would be further supported by findings that antihypertensive agents reverse or reduce
deficiencies previously exhibited by hypertensives. Since untreated hypertensive adults
clearly demonstrate impaired cognitive functioning when compared to normotensives, it
is possible that these effects might be negated by medicinal treatment of high blood
pressure (Muldoon, Waldstein, & Jennings, 1995). Indeed, there is some research that
show antihypertensive medication can improve performance on cognitive tasks.
Miller, Shapiro, King, Ginchereau, and Hosutt ( 1984), in an initial test of 4 1
matched pairs of hypertensive and normotensive subjects, showed that hypertensives
performed less well on a variety of sensory-perceptual tasks, cognitive t�sts, and
psychomotor function tests. Fifteen months later, subjects were retested with the
complete battery of 15 tests. Those subjects who had been placed on anti-hypertensive
medication (N=2 1) in the interim period demonstrated improved performance greater
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than that of untreated hypertensives (N= 13) in 12 of the 15 tests and greater than
normotensives (N=24) on 10 of 15 tests. Untreated hypertensives, on the other hand,
actually performed more poorly on 7 of 15 tests, while making no or insignificant gains
on the other tasks. It is important to note that the only significant changes in blood
pressure across the 15 months were exhibited by the treated hypertensive group. The
authors conclude that medicinal treatment of hypertension restored cognitive functioning
almost to the level of normotensive functioning while untreated hypertensives improved
only slightly or actually deteriorated on the tasks. Of course, the above study is not
experimental in that administration of antihypertensive medicine was not randomly
assigned. Still, the results suggest that blood pressure, as a manipulated variable, can
affect chances in cognitive functioning.
Richards, Emsley, Roberts, Murray, Hall, Gao, & Hendrie (2000) investigated the
association between hypertensive medication and cognitive deficiencies/dementia in a
large (N=22 12), African-American sample. They found that antihypertensive (but not
antidiabetic, antihyperlipidemic, or antithrombotic) medications were associated with
reduced cognitive impairment. The authors suggest that antihypertensive medication may
be one way to reduce the cognitive decline usually associated with aging. These results
have been criticized, however, due to lack of repeated blood pressure measurements and
failure to assess compliance to the antihypertensive treatment (Gambassi, Onder, &
Bernabei, 2001).
A review of the neurophysiological effects of antihypertensive medication yielded
mixed results (Muldoon, Waldstein, & Jennings, 1995). Given the many types of
antihypertensive agents used in studies (beta-blockers, diuretics, calcium channel
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blockers, ACE inhibitors, and central sympatholoytic agents), results are difficult to
compare. In many cases, the possible beneficial effects of lowered blood pressure may be
countered by other activities of the drug. For example, there is some evidence that central
sympatholytic agents may have a negative effect on cognitive functioning (Johnson et al.,
1990). Unfortunately, the medication used to lower blood pressure is a serious confound,
as studies make use of many different drugs, all of which may have either positive or
negative effects on performance through channels other than blood pressure. For this
reason, and because many studies made use of very small sample sizes, the authors of the
meta-analysis conclude that little can be determined concerning the possible effects of
hypertensive medication on cognitive performance (Muldoon, Waldstein, & Jennings,
1995).
Stronger evidence for the physiology-first model of repression/hypertension
comes from experimental manipulation of blood pressure on pain tolerance. Dworkin et
al. ( 1979) induced high blood pressure in rats with an injection of phenylephrine (a post
synaptic adrenergic agonist) while giving a control group of rats an injection of saline.
The high blood pressure group exhibited less escape-avoidance behavior (measured by
amount of treadmill running to deactivate electric shock) than the saline group. The
authors concluded that this effect was due to the attenuated aversiveness of the noxious
stimuli, rather than due to any direct action on the rats' muscular tone or ability to escape.
Zamir and Segal ( 1979) experimentally elevated rats' blood pressure by applying
a solid silver clip on the left renal artery. A control group went through a sham procedure
in which no clip was applied. The rise in blood pressure among the rats with blocked
renal arteries was found to be closely related to a rise in pain threshold. These findings
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support the conclusions offered in the Dworkin et al., ( 1979) study: blood pressure itself,
rather than any particular drug, is the key factor in inducing antinociception (reduction in
experience of pain). By raising blood pressure levels, whether by pharmacological or
surgical means, increased tolerance to painful stimuli can be produced. The rats' behavior
may also be analogous to that exhibited by repressive copers. In both humans and rats,
high blood pressure is associated with less experience of pain and/or pain avoidance.
However, while the repressive coping literature is correlational, the animal research
points to a specific direction: elevated blood pressure causes a reduction in pain
experience or pain expression.
Although a strong case for the role of high blood pressure in diminished cognitive
functioning and increased pain tolerance can be made, potential biological mechanisms
for this relationship need· to be identified. In the Dworkin et al. (1979) study, while
elevated blood pressure did reduce escape-avoidance behavior, it did not reduce that
behavior in rats with surgically denervated baroreceptors (receptors specifically designed
to detect and maintain blood pressure levels). Furthermore, direct stimulation of the
baroreceptors has been found to produce the same behavioral results as raising blood
pressure (Randich and Hartunian, 1983 ; Randich, 1986). Since high blood pressure does
not diminish noxiousness when baroreceptors are deactivated, and since direct
baroreceptor stimulation does reduce noxiousness, the conclusion may be made that
blood pressure operates through activation of the baroreceptors to reduce noxiousness.
Research with naloxone, an opioid antagonist, has further suggested that
baroreceptors may play a role in antinociception through their effect on endogenous
opioids systems. Saavedra ( 198 1) found that naloxone negated the increased pain
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tolerance exhibited by hypertensive rats. Naloxone had no effect on normotensive rats.
These results suggest that heightened pain tolerance found in hypertensive rats is
somehow related to increased levels of endogenous opiates being produced as a result of
stimulated baroreceptors, which are, in turn, activated by elevated blood pressure due to
sympathetic arousal.
Human studies have also supported this finding. Janssen and Arntz (200 1)
injected participants with either naloxone or a saline placebo before having them perform
a first-time parachute jump. After the jump, subjects were given electric shocks while
subjective measures of pain were recorded. Subjects in the placebo group reported
significant! y lower pain experience as compared to those who received the opioid
antagonist. Furthermore, measures of plasma beta-endorphin levels increased greatly
following the jump, further suggesting that the mechanism of pain reduction is through
increased opioid production triggered by sympathetic nervous system arousal.
Functionally, endogenous opiates may serve a purpose in diminishing the stress
response, through their effects on various em?tional and affective systems (Drolet et al.,
2001). Stress appears to be the normal stimulus for the production of endogenous opioids
(Terman, Shavit, & Lewis, 1984). As such, stress-activated opiates may serve a
regulatory/homeostatic role.
The limbic system, in particular, seems heavily affected by the opiate system, as
judged by high concentrations of receptors in the amygdala, hippocampus, hypothalamus,
cingulate cortex, entorhinal cortex, and septum (Drolet et al ., 200 1). All of these
structures, as part of the limbic system, are important in emotion and memory. Through
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effects on these structures, endogenous opiates may regulate the sympathetic system by
reducing the stressful response associated with a stressor.
The role of endogenous opiates in attenuating the stress response (including pain
and negative affect) could well explain correlational results relating hypertension to
repressive coping style. Repression, in the clinical sense of the word, however, also
involves memory, such as in the repression of a traumatic incident. Therefore, for the
endogenous opiate hypothesis to be a reasonable explanation for the formation of
repression, it must also be shown that these neuropeptides have a demonstrable effect on
memory.
While no studies on human subjects have been performed, there is sufficient
evidence from rat research to suggest that high levels of endorphins, when administered
artificially, can serve to block memory processes, specifically through the formation of
retrograde amnesia. Beta-endorphin, one endogenous opiate peptide, was shown to cause
retrograde amnesia (Izquierdo et al., 1 980). Rats were trained to avoid shock in a shuttle
avoidance task. On the last trial, rats given saline still showed evidence of learning;
exhibited by better performance. Rats given beta-endorphin, however, showed evidence
of amnesia as manifested by no improvement over training performance. Beta-endorphins
appeared to wipe out all memory of the task. Furthermore, the greater the dose, the
greater the amnesic effects.
Introduction of beta-endorphin during learning acquisition has also been found to
interfere with long-term memory. Rats given beta-endorphin directly following an
inhibitory avoidance task showed no evidence of learning when tests were performed 24
hours later (Castellano et al., 1993). These results suggest that the lack of avoidance
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behavior cannot be attributed just to the analgesic effect of endorphins. The effect of
beta-endorphin on memory has also been seen in areas other than escape-avoidance, such
as in spatial working memory (Wan, Givens, and Olton, 1995), with administrations of
endorphin resulting in significantly impaired accuracy in mazes. Naloxone, however,
negates the amnesic effects of endorphins, whether those endorphins are introduced
artificially (Flood, Garland, & Morley, 1993, Izquierdo et al., 1980) or produced by the
organism (e.g., as a response to electroconvulsive shock; Carrasco, Dias, and Izquierdo,
1982).
Therefore, in looking at the literature on repression and hypertension, the
following statements can be made: First, there is strong evidence for an inverse
relationship between hypertension and diminished reporting of pain, stress, and negative
affect. Second, the inverse blood pressure/pain sensitivity relationship can be induced in
normotensives with experimentally manipulated, heightened blood pressure. Third, little
evidence supports the hypothesis that repression causes increases in blood pressure or the
development of hypertension. Fourth, experimentally induced increases in blood pressure
and baroreceptor activity in rats has resulted in behaviors similar to those of human
psychological repression. Fifth, research on the introduction of opiate antagonists to
humans and animals suggests that the antinociceptive effects of high blood pressure are
largely due to endogenous opiate activity. Sixth, endorphin-mediated cortical suppression
has resulted in memory difficulties similar to those of repression.
The primary function of baroreceptors is the maintenance of proper blood
pressure levels. More specifically, they ensure that the brain receives an optimal level of
blood across different activities and stressors. Blood pressure levels above optimal could
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result in cerebrovascular damage, including stroke. In the case of stress-induced
elevations of blood pressure, baroreceptor activity triggers quick recovery of blood
pressure levels by acting on cardiovascular functioning via the medulla oblongata. The
resulting activity reduces norepinephrine (sympathetic output) and increases
acetylcholine (parasympathetic output) levels, thus decreasing blood pressure through
reduced heart rate and increased vasodilation. However, limbic and neocorticol
influences (i.e., conscious experience of threat) may also necessitate an additional,
indirect path for suppressing the sympathetic response. Psychological factors (e.g.,
distress, fear) contributing to heightened blood pressure may also have to be suppressed
in order to regain a homeostatic balance in cardiovascular functioning. The endogenous
· opioid system may have evolved as the mechanism for inhibiting these psychological
influences.
The endogenous opioid system, acting on many limbic structures of the brain,
decreases the experience of stress and pain. The net effect of these opiates, when
triggered by baroreceptors, may be the diminishing of psychological stress for the
purpose of lowering blood pressure levels. An individual experiencing the effect of high
levels of opiates would likely experience less pain and stress, and feel less threatened by
psychological stressors, consequentially reporting less pain, less stress, and less negative
affect. These signs, together with heightened blood pressure levels, are the exact set of
behaviors that repressive copers present in laboratory studies. As suggested by others (see
Nyklicek, Vingerhoets & Van Heck, 1998) the repressive coping style, as a psychological
phenomenon, may be the result of a physiological state, mainly, elevated blood pressure,
baroreceptor activity, and endogenous opioid levels.
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While the literature .ls suggestive of a causal role of hypertension in repressive
phenomena, this hypothesis has never been specifically tested. In order to more fully
understand the relationship between the two conditions, previous research must be
extended beyond physical pain, to include concepts more cognitive in nature. The present
experiment is designed to test the hypothesis that endogenous opioids mediate the
relationship between hypertension and repression. If endogenous opioids are the
mechanism in this relationship, opioid antagonism should decrease repression and
increase disclosure.
In the present study, normotensives and hypertensives participated in four
laboratory sessions in which they verbally disclosed their current concerns, stressors, and
feelings. Following the narratives, participants filled out scales measuring levels of
repression and disclosure. These measures included a measure of life concerns and an
index of repressive coping (The Index of Self-Regulation of Emotion; Mendolia, 2002)
which is a composite of social desirability and manifest anxiety scales. In two of the
sessions, individuals were administered naltrexone, an opioid antagonist. In the other two
sessions, a placebo was administered. Administration was double-blind and the schedule
was randomized.
Planned comparisons were used to test the hypothesis that naltrexone would
significantly alter the self-reports of hypertensives, but not normotensives, in the
direction of less repression and greater disclosure . In planned comparisons, real
differences among means are more likely to be detected (Glasnopp & Poggio, 1985).
These tests are more powerful than post hoc tests and are thus recommended when
comparing means (Pedhazur, 1982). Furthermore, planned comparisons reduce spurious
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findings by reducing the total number of tests and minimizing the impact of chance
(Thompson, 1988). As low subject numbers would prevent sufficient power to run initial
interaction analyses, the effects of naltrexone were statistically tested separately on each
the normotensive and hypertensive groups. If naltrexone was found to significantly affect
the dependent variable of repression/disclosure on hypertensives, but not normotensives,
this finding would lend_ support for the role of endogenous opioids in mediating the
hypertension/repression relationship.
In addition to the two main dependent variables (life concern disclosure and
repressive coping), a number of measures were included to test discriminant validity and
measure potential confounds. If naltrexone was found to increase disclosure of negative
events and experiences, it might be argued that the change was due purely to decreased
mood. If individuals experienced physical symptoms such as fatigue or nausea, they may
feel worse and thus report more negative experiences. Because naltrexone has been
reported by some early investigators as negatively affecting mood (Mendelson,
Ellingboe, Keuhnle, & Mello, 1979; Hollister, Johnson, Boukhabza, & Gillespie, 198 1), a
measure of mood states was included in the present study to study the possible
confounding effects of mood. The Profile of Mood States (POMS; McNair, Larr, &
Dropplemen, 197 1), used in the present study, is a standard measure of mood in similar
investigations.
As endogenous opioid antagonism is known to affect perception of physiological
pain (e.g., Janssen and Arntz, 200 1), a test of pain was provided by the inflation of a
blood pressure cuff prior, during, and following the interview period. Although the pain
evoked by the readings is usually minimal, it is possible that experienced pain would
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increase with opioid antagonism. If pain perception is increased, it might be argued,
similarly to mood, that increased reporting of negative affect was due to increased
physiological pain. Following the last blood pressure reading, participants were asked to
rate the pain experienced from the cuff. These ratings were used to determine if
experienced pain increased with opioid antagonism and if physiological pain could
potentially confound results obtained with the main dependent variables of repression and
disclosure.
Alexithymia is a condition defined by difficulty in recognizing emotional states,
problems with articulating emotions, a highly mechanical, analytical, and externally
oriented thinking style, and possibly an impoverished fantasy life (Sifneos, 1996; Parker,
Bagby, Taylor, Endler, & Schmitz, 1993). Although repressive coping and alexithymia
are thought to be independent phenomena, they share some common traits, such as
inability to express emotion (although the repressive coper may selectively inhibit the
expression of dystonic emotions). As the cognitive-affective disturbances evidenced by
alexithymics (see Taylor, 1984) are likely dif!erent in origin than than those evidenced by
repressive copers, a scale of alexithymia (Taylor, Ryan, & Bagby, 1985) was included in
the present design to provide discriminant validity. Endogenous opioid antagonism, and
thus the drug naltrexone, should have no effect on alexithymic symptoms.
Finally, conscious knowledge of the drug condition could affect material provided
in interviews and responses to self-report measures. If participants knew when they
received the active drug, they might behave as they expect they should under such a drug.
While participants were not told of any possible cognitive and emotional effects, they
were informed of the drug's effect on analgesic systems. To serve as a manipulation
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check, subjects were asked to guess, at the end of each session, whether they received the
drug or placebo. If participants could correctly guess which substance they had received,
their behaviors might be influenced by such knowledge.
While no cardiovascular effects of naltrexone have been reported, the effects of
the drug on systolic and diastolic pressure where measured. If high blood pressure is
maintained in order to hold endogenous opioid activity at a certain level, then antagonism
of those opioids might drive systolic blood pressure higher in an effort to restore
equilibrium. To the extent that blood pressure is responsible for the maintenance of
opioid levels, blood pressure should rise, by way of compensation, whenever those opioid
levels fall. Therefore, we would expect blood pressure levels to be higher among
individuals under the drug condition. If the blood pressure-opioid-repression condition
holds only for hypertensives, however, we would not expect such a change in
normotensives. While changes in systolic and diastolic blood pressures are affected by
different mechanisms (cardiac output and vasodilation, respectively), both may increase
under acute stress. Because systolic blood pressure has been found to be more reactive
during social tasks (such as giving a personal interview), it might be expected that
systolic pressure would be more strongly affected than diastolic in the present study.
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CHAPTER II: METHOD

Participants
Male, undergraduate students were solicited via extra credit announcements for
the Department of Psychology at the University of Tennessee. Volunteers were invited to
participate in a short cardiovascular/medical screening procedure for nominal extra credit
in a psychology course. The screening sample consisted of 1 25 individuals.
After signing the consent from, participants completed a blood pressure screening
procedure. Readings were taken with a Critikon Dinamap 1 846 Vital Signs Monitor at 2minute intervals for a 1 5-minute period. Resting levels were calculated by averaging the
last 3 readings. Volunteers were considered potential participants in the experiment if
their systolic blood pressure fell in the upper or lower 1 0th of the screening distribution.
Following the cardiovascular screening period, participants were given a short
medical history questionnaire. The questionnaire screened for two types of conditions: 1 )
secondary causes of hypertension and 2 ) conditions contraindicated with the
administration of naltrexone. Because the most common causes of hypertension in young
adults are renal disease and diabetes, causes of secondary hypertension focused on signs
and symptoms of these disorders. Those reporting diabetes or kidney problems were also
excluded from further participation. Furthermore, those reporting symptoms common in
renal disease Gaundice, chronic fatigue, chronic nausea, chronic fever, "foamy" urine,
difficulty urinating, painful urination, blood in urine, or swelling in the hands, feet or
around the eyes) were excluded from the study.
A number of conditions considered dangerous with administration of naltrexone
were also screened out. These conditions and situations include: alcoholism, narcotic
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abuse, use of narcotic medication, and hepatitis. Furthermore, although naltrexone has
not been found to have a significant impact on mood (Hatsukami, Mitchell, Morley,
Morgan, & Levine, 1986; Malcolm, O'Neil, Von, & Dickerson, 1987; Miotto, McCann,
Basch, Rawson, & Ling, 2002), participants were screened for depression, dysphoria, or a
history of mental disorders. Lastly, participants were instructed to list all current
medications, and those taking medication contraindicated with the use of naltrexone
(primarily narcotic analgesics) were screened out from further participation. Participants
indicated on a form whether or not they would be interested in continuing with the study,
should they be selected. Five individuals who met cardiovascular criteria were screened
out for one of the above reasons. Two reported histories of significant psychological
distress, one reported excessive medication use, one reported excessive alcohol
consumption and one reported an excessive number of allergies.
From those individuals who were not screened out for medical reasons, 12 were
selected for the normotensive group and 12 for the hypertensive group. These individuals
were contacted, given a brief overview of the study and invited to return to the lab for a
second assessment of their blood pressure status and further information on the study.
Individuals selected for the study were paid $50 for their participation. Twenty-two
individuals, eleven in each the hypertensive and normotensive groups, accepted the
invitation to participate in the experiment. Of these individuals, two withdrew before
their first session, citing concern (or parental concern) over the use of drugs in the
experiment. Both of these individuals were in the normotensive group. One further
individual was terminated by the experimenters due to a missed first session. This
individual was deemed to be an unreliable participant for the experiment.
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The remaining sample, all male, ranged in age from 18 to 25 years (mean 20.28
years). The participants were all Caucasian, with the exception of one African-American,
who was in the hypertensive group.
Measures
The abbreviated version of the Profile of Mood States (POMS; McNair, Larr, &
Dropplemen, 197 1) contains 30 positive and negative emotional states (such as tense,
lively, sluggish, and angry) to which the participant indicates to what degree they have
felt that way in the past week. Responses are made on a Likert-type, 5-point scale. The
subscales of the abbreviated version has yielded alphas ranging from .66 to .95, with a
mean of .80, indicating good internal consistency.
Disclosure of life concerns was measured by the Life Concerns Checklist (LCC;
Rayner & Price, 1989). The LCC contains 34 areas in which a person may be concerned
about in his life. Examples of items are: "conflict with loved ones," and "feeling
inadequate as a person." Respondents indicate, on a 3-point scale, whether they are never
concerned, somewhat concerned, or very concerned about each area. The scale has good
test-retest reliability over 5-weeks (r = .85, p < .0 1). Internal reliability, measured with
the Kuder-Richardson formula for scales with unidimensional constructs, was high (rKK
= .93).
The most wi�ely used method of measuring repressive coping style is to cross the
scores of two scales: the Taylor Manifest Anxiety Scale, Bendig Short Form (MAS;
Bendig, 1956) and the Social Desirability Scale (MCSDS; Crowne & Marlowe, 1 960).
The MAS contains 20 items measuring anxiety, such as, "I often find myself worrying
about something" and "I am more self-conscious that most people." Individuals respond
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to each statement with true or false. The MCSDS contains 33 items that measure how
defensi�e one is about their own behavior or thoughts. Examples include, "I never resent
being asked to return a favor," and "I have never deliberately said something that hurt
someone' s feelings." Respondents indicate whether the statement is true or false in
describing them. Repression was measured with the most recent method of subtracting
the MCSDS score from the TAS, which yields the Index of Self-Regulation of Emotion
(ISE; Mendolia, 2002). This method provides a continuous measure of the MCSDS/fAS
relationship. High-anxious individuals have lower scores on the spread while repressors
occupy the higher end of the index. Low-anxious and defensive high-anxious make up
the middle portion of the spread.
Alexithymia was measured with the Toronto Alexithymia Scale, 20-item version
(TAS ; Taylor, Ryan, & Bagby, 1 985). The TAS contains items such as, "I have feelings
that I can't quite identify" and "I prefer to analyze problems rather than just describe
them." Respondents reply on a 5-point, Likert-type scale. Endorsement of the items
suggests high alexithymic traits. The 20-item version of the TAS has been found to have
high internal consistency (a = . 85)
As endogenous opioids are known primarily for their antinociceptive/analgesic
properties, most experimental research has been conducted on the effect of opioid
antagonists on pain. As previous research has found opioid antagonists to increase
experienced pain in hypertensives but not normotensives, blood pressure cuff pain was
measured in the present study as an attempt at replication. Blood pressure measurements
were taken at 2-minute intervals for 5 minutes prior to each interview (baseline). These
measurements continued for the duration of the interview (task) and for 2 minutes
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following the interview (recovery). Because inflation of the cuff necessitates the
occlusion of the blood vessels, a certain amount of ischemic discomfort may be expected.
Most individuals typically find this discomfort to be minimal, however, some find the
pressure painful. Following each session, the participants were asked to rate, from 1 to
10, how painful they found the blood pressure cuff inflation for the duration of the
measurement process.
Materials

Experimental manipulation of opioid activity was achieved with the opioid
antagonist naltrexone, which is frequently used in treatment of narcotic dependency
(Malcolm, O'Neil, Von, & Dickerson, 1987). Naltrexone effectively blocks activity at mu
and kappa opioid receptors (Preston & Bigelow, 1992). It is orally absorbed, reaches
peak absorption levels in an hour, and has a half-life of approximately 4 hours (Martin,
Straughn, Lo, Schary, & Whitney, 1984). In healthy volunteers, naltrexone has not been
shown to present any significant adverse effects (Martin, Jasinski, & Mansky, 1973).
Revia brand naltrexone is administered as a 50mg tablet. For the present
experiment, these tablets were inserted into a green opaque gelcap, in order to maintain
similarity in appearance with the placebo. An equal amount of nonactive substance (sugar
pill) was placed in a gelcap to serve as the placebo.
Procedures

Participants who met blood pressure requirements on the two assessment periods
were asked to schedule four lab visits over a two-week period, with each visit lasting
approximately 1 hour and 45 minutes. Upon arrival, participants were administered either
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the naltrexone or placebo, in a double-blind, randomized fashion. Each participant was
given the active drug on two occasions and the placebo on two occasions.
Following drug or placebo administration, participants were seated and their
cardiovascular group status (high or low) was reconfirmed. Following confirmation of
group status, participants waited for 1 hour to allow for peak absorption of the drug.
During this time, participants were allowed to bring their own work or they could choose
between pre-screened television programs, video games, and magazines. Available media
were screened to insure the absence of strong emotional content that could confound later
data collection of affective states.
Following the one-hour absorption period, blood pressure was again checked.
Blood pressure state was assessed with three readings taken at two minute intervals.
These readings both established a baseline level for pre-interview cardiovascular status
and allowed tests to be conducted on the cardiovascular effects of the opioid antagonist.
Following baseline cardiovascular measurements, participants completed the
interview stage. These interviews were audiotaped for later transcription and analysis.
Blood pressure measurements continued at two-minute intervals throughout the duration
of the interview. Participants were asked three questions, which were not
counterbalanced for order by session. Following each question, participants were given
20 seconds to think of a response and were then allowed to describe their response.
Participants were first instructed to, "Let your mind wander for a short period. After
about twenty seconds, you can describe to me what you were thinking about." Secondly,
participants were instructed to, "Think for a few moments about the past 24 hours.
Review the events, good, bad, and neutral, in your mind. In a few moments, I will have
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you describe those events and generally how the last 24 hours went in as much detail as
you would like." Finally, participants were asked, "What is the one thing that is causing
you the most stress, anxiety, or concern right now? Think about that for a few moments
and then you can describe that situation to me." Participants were allowed to respond to
the questions without interruption and no followup questions were asked. This open
ended approach allowed the coding of spontaneous disclosure (both length and depth)
and minimized confounding by interviewer biases.
Following the narrative, participants filled out the scales of repression/disclosure:
POMS, LCC, positive and negative valenced descriptors, TAS, and MCSDS. Two
additional blood pressure measurements were taken during this period to serve as a
pseudo-recovery period.
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CHAPTER III: RESULTS
Early Termination

Of the individuals who attended the first session, only one terminated before
completion of the 4-session protocol. The participant, in the hypertensive group,
withdrew from the experiment after the first session. In the first session, baseline readings
averaged 1 35/72 mrnHg. During the interview, the subject talked very little, but exhibited
large blood pressure increases in reaction to talking about a test which was imminent.
Blood pressure levels averaged 1 57/1 1 5 mmHg during the interview period. The
participant withdrew from the study the day after the first session, citing negative side
effects of the drug. Specifically, he mentioned "getting into fights" with people on the
internet, and "feeling his blood pressure rise." He attributed these experiences to the drug.
He also tried playing basketball the evening of the first session but was unable to
continue due to fatigue. The participant went to bed early and felt fine the next day. After
officially terminating the participant, it was confirmed that he did receive the active drug
on the first session. The individual was paid $5 for his participation in the first session.
Group Differences

Blood pressure levels were measured on three separate dates to insure accuracy of
hypertensive or normotensive status. The first date was in the initial
cardiovascular/medical screening which determined group status. Independent t-tests
indicated a clear distinction in both systolic (SBP; t( l 6) = 1 8.0, p < .000 l ) and diastolic
(DBP; t( l 6) = 3.9, p < .000 1 ) blood pressure.
After a minimum of one week after the initial screening, participants returned to
the lab for blood pressure confirmation. Figure A- 1 (all figures and tables are located in
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the Appendix) presents the groups differences in SBP and DBP. As can be seen in the
boxplots, there was no cardiovascular overlap between the groups when reassessed one
week later. Independent t-tests confirm that SBP (t(l 6) = 13 .8, p < .000 1) and DBP (!( 1 6)
= 6.2, p < .000 1 ) remained significantly different between groups. The cardiovascular
means for each participant are presented in Table A- 1 . Reported means were calculated
by averaging the last 3 readings taken during the screening (a) and confirmation (b)
sessions.
As body mass is a known factor in elevated blood pressure, the body mass index
(BMI) was calculated for each subject. BMI is a better measure of obesity than weight
alone and is calculated with the following formula: (weight [lbs] x 704.5) I (height [in] x
height). BMI was significantly different between groups (t( 16) = -.37, p = .002) with
hypertensives having a higher BMI (mean = 24.9, sd = 1.8) than normotensives (mean =
22.0, sd = 1.4). Therefore, in all tests involving cardiovascular dependent measures, BMI
was included as a covariate.
Groups did not differ on age (t( l6) = -.5 (p=.617). No other variables were
assessed.
Main Analyses: Effects of Naltrexone Administration

As the sample size was too small to test for interaction effects, simple effects for
drug/placebo were tested separately for the normotensive and hypertensive groups,
according to a priori hypotheses. Custom contrasts were used to compare the drug and
placebo sessions.
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Conjounds and controls
Before analyses on main dependent variables were conducted, potential
confounding variables were tested. These variables included pain, mood, and
participants' guess of drug status.
Pain ratings, provided by the participants following the last blood pressure
reading of each session was tested as a function of drug/placebo condition. No significant
drug/placebo effect was found for either hypertensives (F( l ) = 0.00 (p = 1.00) or
normotensives (F( l ) = 3.769 (p = . 1 10). Therefore, both groups failed to respond
differentially to drug/placebo conditions. Most likely, blood cuff pain served as a poor
measure of pain sensitivity, as the pain was not constant (as with a dedicated cold-pressor
or finger-pressor procedure) and most individuals do not find the inflation to be
uncomfortable.
Consistent with the most resent research on naltrexone and mood, there was
generally little effect for drug condition on mood, as measured by the Profile of Mood
States. The anger, confusion, fatigue, depression and vigor subscales were unrelated to
drug condition in either group. The tension subscale was significantly related to drug
condition in normotensives (F( l ) = 20.86, p = .003) but not in hypertensives (F( l ) = .0 18,
p = .90). As seen in Figure A-2, normotensives reported significantly greater tension

during the drug condition while hypertensives remained unchanged.
Chi-square analyses were used to determine whether or not participants could
accurately assess whether they had received the drug or placebo. Neither hypertensives (X
= .48, p = .59) nor normotensives (X = 1.8, p = .22) guessed their drug or placebo

condition over chance accuracy.
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Further control was provided with the Toronto Alexithymia Scale, as the
condition is thought to have origins distinct from repressive coping, despite some
superficial similarities between the two conditions. There was no significant effect for the
drug condition on alexithymic traits in hypertensives (F( l ) = .05, p =.82) or
normotensives (F( l ) = 3.04, p = . 12). Participants experienced no change in alexithymic
symptoms as a result of opioid antagonism.
Drug effects on repression/disclosure
Contrasts revealed a significant main effect for the drug condition on
hypertensive's reporting of life concerns (F( l ) = 5.07, p = .05). As seen in Figure A-3,
hypertensives disclosed significantly greater life concerns when under the active
naltrexone sessions. Life concerns reported by normotensives did not change as a
function of drug/placebo (F( l ) = .0 1, p = .944).
As measured by the Index of Self-Regulation of Emotion, hypertensives exhibited
significantly less repressive coping in the drug condition (F( l ) = 20.83, p = .004).
Normotensives, however, showed no signific�t change (F( l ) = .73, p = .427). Figure A4 presents the differential responding of hypertensives and normotensives to the drug
condition. Although it appears that normotensives in the drug condition display a greater
tendency towards repressive coping, it is important to note that this difference is not
significant.
Cardiovascular effects
As no cardiovascular effects for opioid antagonism have been reported in
previous studies, the potential effects of naltrexone on blood pressure was investigated in
the present study. If hypertension is related to endogenous opioid systems, the
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manipulation of one system might have a demonstrable effect on the other. Blood
pressure measurements were taken at 2-minute intervals for six minutes prior to each
interview (baseline), during the interview (task), and for 2-minutes after the interview
(recovery).
Systolic blood pressure was compared for high and low pressure groups across
drug conditions in the baseline, task, and recovery phases. The drug condition had a
significant effect on systolic blood pressure during interview (F(1) = 24.14 (p=.001) and
recovery (F( l ) = 7.50 (p = .02) for the hypertensive group but not for the normotensive
group (F( l ) = .0, p=I .0; F( I) = .62, p = .49). Hypertensives exhibited significantly higher
systolic blood pressure levels during the interview when in the drug condition as
compared to the placebo condition. For normotensives, there was no significant
difference in levels during the interview. Figure A-5 presents systolic levels over the
three phases for hypertensive and normotensives in the drug and placebo conditions. As
can be seen in the graph, normotensives exhibited the same response whether under the
drug or placebo. In hypertensives, however, the drug condition produced significantly
higher systolic levels under the interview. No effects were found for drug on diastolic
blood pressure.
Narrative effects

Total number of words contained in the participant narratives were counted. A
general contrast found a significant main effect for drug condition (F( 1)=7. 2 1, p=.02). As
seen in Figure A-6, both the hypertensive and normotensive groups were similarly
affected by the drug condition. Both groups provided more words in their narratives
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under the drug condition, supporting the hypothesis that the drug condition increases
disclosure.
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CHAPTER IV: DISCUSSION
A good body of literature has reported a positive relationship between
hypertension and diminished reporting of stress and negative affect (e.g., Cumes, 1 983;
Handkins & Munz, 1978; Winkleby, Ragland & Syme, 1 988; Davies, 1970; Rose,
Jenkins & Hurst, 1978). Very few studies, however, have attempted to discover the
nature or mechanisms of this relationship. While many clinicians and theoreticians have
hypothesized a model in which inhibited affect manifests itself somatically (e.g.,
Esterling, Antoni, Kumar & Schneiderman, 1990; Shedler, Mayman, and Manis, 1 993),
little evidence has been brought forth to support this claim. Likewise, while studies have
found manipulation of physiological factors (such as blood pressure and endogenous
opioid levels) to affect pain perception (e.g., Jannsen & Arntz, 200 1), no attempts to
extend this model to repressive phenomena have been made. The present study presents
perhaps the first attempt to test the model that altered physiology, specifically the levels
of endogenous opioids controlled by blood pressure, can affect the manifestation of
repressive coping phenomena.
Eighteen participants, 10 hypertensive and 8 normotensive, were administered
naltrexone, an opioid antagonist, or a placebo across four laboratory sessions according to
a randomized and double-blind schedule. In each session, measures of disclosure and
repressive coping were collected. Overall, the drug condition was found to reduce
repressive phenomena and increase disclosure in hypertensives only, supporting the
hypothesis that cardiovascular-controlled opioids are, at least partially, responsible for the
diminished responding evidenced by hypertensives.
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Summary of Findings
Controls and potential conjounds

Discriminant analyses and tests of potential confounds were performed on four
variables: pain, mood, alexithymia, and the manipulation check (participants guess of
drug/placebo condition).
First, increased experienced physiological pain and negative mood are two areas
in which opioid antagonism may have an effect. Since increased pain and a more
negative mood could influence responses to narrative questions and self-report scales,
these variables were included in the study design. Neither the hypertensive nor
normotensive group experienced greater pain as a function of the drug condition. Levels
of pain reported from the blood pressure cuff were similar across drug/placebo
conditions. Therefore, it is unlikely that increased physiological pain was responsible for
increased disclosure.
The Profile of Mood States is a popular measure of general mood with subscales
for tension, depression, anger, fatigue, vigor, and confusion. While a small number of
studies have found a negative effect of naltrexone on mood (Mendelson, Ellingboe,
Keuhnle, & Mello, 1979; Hollister, Johnson, Boukhabza, & Gillespie, 1981), these
studies have been criticized for small sample sizes and lack of appropriate controls
(Malcolm, O'Neil, Von, & Dickerson, 1987). Recent studies have failed to find any
dysphoric effects of naltrexone (Hatsukami, Mitchell, Morley, Morgan, & Levine, 1986;
Malcolm, O'Neil, Von, & Dickerson, 1987) and a review of the literature found no
evidence for a significant effect on mood (Miotto, McCann, Basch, Rawson, & Ling,
2002). If naltrexone significantly alters mood, those mood changes may be responsible
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for effects observed in the repressive scales. In other words, perhaps naltrexone just
makes people feel bad and this is why there is more observed disclosure. The results of
the present study do not support this hypothesis of a possible confound, however. Five of
the six subscales were unrelated to drug condition in either the hypertensive or
normotensive groups. The one subscale with significant differences, tension, was
significant only in the normotensive group. Therefore, significant results for disclosure
observed in the hypertensive group are unlikely to be caused by alterations in mood.
Participant's knowledge of their drug/placebo condition may influence their
responses to interview and scale questions. Results show that participants fared no better
than chance at guessing whether they received the drug or placebo. Therefore,
psychological differences were found (decreased repression and increased disclosure)
despite no consciously-experienced, internal change in the participants. This finding is
important for two reasons; first, it adds strength to the repression/disclosure findings by
suggesting they are not simply the result of somatically-experienced changes. Second, it
shows that the effects of endogenous opioids may be stronger on repression and
disclosure than on the systems (pain, mood) with which opioids are traditionally linked.
The results from the pain, mood, and guess measures suggest that none of these factors
were responsible for psychological differences found between placebo and drug
conditions.
Finally, although alexithymia and repressive coping are observed to share
common traits, such as impairments in emotion recognition (Lane, Sechrest, Riedel,
Shapiro, & Kasniak, 2000), evidence suggests that these two phenomena are independent
(Newton & Contrada, 1994). In fact, despite their superficial similarity, repressive capers
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score extremely low on scales of alexithymia (Myers, 1 995). Since alexithymia is also
found in greater proportions among hypertensives (Todarello, Taylor, Parker. & Fanelli,
1 995), a scale of alexithymia was included in the present study to assess whether
alexithymia traits might be similarly affected by opioid manipulation. If alexithymia is
independent from repressive coping and involves different physiological and neurological
conditions in its genesis and maintenance, opioid antagonism should have no effect on
alexithymia scores. Indeed, neither the hypertensive nor normotensive group were found
to differ on alexithymia scores as a function of drug condition, therefore, it was
concluded that alexithymia does not share physiological aspects with repressive coping.
These findings support the general finding that alexithymia and repression are separate
constructs. Furthermore, it supports the hypothesis that opioid antagonism has specific
effects on certain psychological phenomena (repression and disclosure) while not
affecting other similar, but independent, constructs.
Repression and disclosure
While adequate power existed for th� within-subjects drug variable, there was
insufficient power to conduct tests of group differences (normotensive versus
hypertensive), due to small sample sizes. Therefore, a priori comparisons were
developed. Specifically, it was hypothesized that the drug condition would have a
significant effect on hypertensive disclosure but not normotensive disclosure. The
obtained results support these hypotheses. While analyzing groups separately for drug
effects does not determine whether slopes are different for the two groups, it does provide
a basis for saying the drug condition affects one group but not the other.
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Two measures were included to test the effects of the drug naltrexone on
disclosure. The Index of Self-Regulation of Emotion is a composite score of the Marlow
Crowne Social Desirability Scale and Taylor's Manifest Anxiety Scale which provides a
measure of repressive coping. High repressive copers are those individuals who report
low levels of anxiety but also present high levels of social desirability. Planned
comparisons showed that naltrexone significantly decreased repressive coping in
hypertensives but not in normotensives. Therefore, the repressive coping demonstrated by
hypertensives appears to be significantly altered by opioid antagonism. As repressive
coping is linked with an impaired ability to recall negative events and material (Myers &
Brewin, 1995; Myers, Brewin & Power, 1998) and overly positive evaluations of the self
(Myers & Brewin, 1996), the presence of repressive coping may be an obstacle to
therapy. Research has long found that repressive copers claim low levels of anxiety,
despite physiological indices that indicate repressive copers are more reactive to stress
than any other group (Weinberger, Schwartz & Davidson, 1979).
Previous research has also found that hypertensives report fewer life concerns
(Rayner & Price, 1989) than normotensives. Again, the unrealistic reporting of concerns
and problems would pose potential problems for both personal relationships and
psychotherapeutic ones. In the present study, the Life Concerns Checklist was used as a
measure of self-report of concerns. Under the drug condition, hypertensives reported
significantly more life concerns. Normotensives exhibited no significant changes in life
concerns. Thus, hypertensives exhibited a differential reaction to opioid antagonism as
compared to placebo whereas normotensives did not.
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Narrative effects

Because repressive coping is a condition that likely reduces disclosure in
therapeutic settings, participants completed a short interview at each visit. Participants
were asked to free associate and describe what they thought about, describe the last 24
hours, and describe their most pressing concern or stressor. In this way, the usefulness of
naltrexone as an acute tool in therapy could be assessed. Crude analyses of provided
narratives partially supports the hypothesis that opioid manipulation alters verbal
communication. Both hypertensives and normotensives spoke significantly more in the
drug condition. Across hypertensives and normotensives, individuals were observed to
speak an average of 20% more in the drug condition. These results warrant the further
investigation of opioid processes on the quality of oral narratives.
Cardiovascular effects

Of particular interest were the cardiovascular effects of the drug condition.
Hypertensives under the stress of the interview exhibited significantly higher systolic
blood pressure levels with administration of naltrexone than with administration of
placebo. These effects were only seen with systolic blood pressure, only in the interview
condition, and only with hypertensives. These results would be predicted by the opioid
peptide theory of hypertension/repression. As stated earlier in the introduction,
individuals with hypertension may have chronically elevated levels of endogenous
opioids. The activity of these opioids on the limbic system may produce the collection of
phenomena generally known as repressive coping. The net result of this opioid activity
would be to diminish the perception of negative stimuli. Therefore, individuals with
chronically elevated levels of opioids would experience negative stress and affect less

43
than their normotensive counterparts. An acute stressor (such as a disclosing interview)
would produce a large sympathetic opioid response which would diminish experienced
stress and thus minimize the cognitive experience of threat that would further increase
blood pressure. In susceptible individuals, however, the inhibition of this system (as with
opioid antagonism) would remove the primary coping strategy used by these individuals.
Therefore, negative emotional experience would not be attenuated and increased stress
would drive blood pressure even higher. More directly, hypertensive-repressors who rely
strongly on endogenous opioids for coping would find events more stressful if those
systems were removed. This increased stress would in tum invoke higher systolic blood
pressure levels. Figure A-7 graphically represents the theoretical stress-opioid feedback
system under normal circumstances and opioid antagonism. Endogenous opioids act as a
moderator between objective stressors and subjective stress by attenuating experienced
distress. Inhibition of these opioid systems, then, would increase experienced stress and
lead to the elevated blood pressure levels observed in the present study.
Implications
Relationship deficiencies in the hypertensive individual
A small literature suggests that hypertensives may possess an altered basis of
negative stimulus appraisal (Nyklicek, Vingerhoets, & Van Heck, 1996; Winkleby,
Ragland, & Syme, 1988). In particular, hypertensives seem less able to detect negative
emotive cues in others (Sapria et al., 1971). If hypertensives are less able to detect anger,
hostility, or other negative affective states in others, their ability to adjust behaviors to
relieve tension may be reduced. Hypertensives, therefore, may not see serious
circumstances for what they are and may minimize the impact of their actions on
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relationships. These hypotheses have been supported by previous literature on essential
hypertension and familial interactions. Hafner and colleagues (1983), measured the
marital quality of twenty-five men and twenty-six women with essential hypertension.
Spouses of hypertensive males reported significantly higher marital dissatisfaction than
spouses of normotensive males. Similarly, there was a lack of congruence between
spouses' scores with the hypertensive females. The authors concluded that anecdotal
reports connecting hypertension with marital discord and communication problems were
supported.
In another study, the family dynamics were examined in families with both
normotensive and hypertensive fathers. In families with hypertensive fathers, gaze
aversion during negative verbalizations occurred significantly more than in families with
normotensive fathers (Baer et al., 1983). In a second study, families with hypertensive
fathers were characterized by less direct coping and an avoidance of conflict resolution.
The authors concluded that conflict styles modeled by the hypertensive father may have
adverse effects on the family and, more specifically, on the child.
Hypertension, often considered "symptomless" condition, may have important
and negative psychological and relationship consequences. Ironically, one of the
symptoms of hypertension may be the inability to notice or the minimization of other
symptoms of the disease. A hypertensive individual may not only feel fine, but also have
a condition that, when removed, makes them feel worse (as the curing of an opioid-addict
would be painful to the patient). Under these circumstances, patients may be resistant to
the treatment of hypertension, perhaps contributing to the prevalence of the condition.
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Implications for psychotherapy
The results of the present study bear important implications for psychotherapy,
particularly in the treatment of hypertension, repression, or co-morbid instances of the
two. The first important implication is that hypertensives may be particularly difficult
patients to treat in a psychotherapeutic environment. Many hypertensives would be
unable, or unwilling, to access negative material for presentation in a clinical session.
Previous studies have shown that hypertensives are less likely to disclose personal
information in both interview and questionnaire format (Berglund, Ander, Lindstrom &
Tibblin, 1975; Weiner, Singer & Resier, 1 962; Handkins & Munz, 1 987; Cumes, 1983;
Cumer-Rayner & Price, 1 98 1 ). This inability or unwillingness to disclose personal
information has been cited as a factor which can potentially render an individual
unsuitable for psychotherapy (Shands, 1 977). Therefore, hypertensive individuals may
make exceptionably difficult patients, especially for insight-oriented therapies.
Second, case studies (e.g., Mann & Delon, 1 995) have shown a direct correlation
between disclosure of traumatic material and large drops in sustained hypertension.
Temporal resolution of these studies, however, were insufficient to determine which
factor, the disclosure or the blood pressure drop, came first. While the classic
interpretation of such results is that the disclosure brought about a change in blood
pressure, recent evidence, including the present study, suggest that the converse might be
more accurate. If repressive phenomena are driven by cardiovascular-regulated
endogenous opioid levels, large drops in blood pressure may allow "repressed" material
to surface. Also, if the symptoms of repressive coping are maintained primarily by
physiological mechanisms, attempts at controlling hypertension via psychotherapeutic
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techniques would be ineffectual. Therefore, psychotherapeutic techniques may not be an
effective route to reducing hypertension. Furthermore, in cases of comorbid
repression/hypertension, the hypertension may have to be addressed before meaningful
psychotherapy can occur.
Third, as the effects seen in the present study apply across the normotensive
range, the therapeutic environment, to the extent that it is a stressful one, could also cause
the exact physiological changes that facilitate the repression or attenuation of negative
affect. The normal sympathetic response to a stressful situation may be an obstacle to
therapeutic progress. While efforts to maintain a stress-free therapeutic environment
would lessen the impact of stress-induced opioid activity, there is little that could be done
to prevent acute stress brought about by discussion of a personal trauma. In essence, as
one gets closer to stressful material, the natural sympathetic response and subsequent
opioid activity could impede further progress. Ironically, this phenomenon would present
itself precisely when the client would need to be least repressive. While the exact
manifestations of this response are unknown, it could involve forgetfulness, minimization
of the new material, confusion, or perhaps laughter. This phenomenon may manifest
itself in the same way as a classically interpreted psychological defense, but its successful
navigation may lie more in controlling the sympathetic response than in examining the
unconscious motives behind the defense.
The present study, while far from sufficient to recommend naltrexone as an aide
to psychotherapy, certainly warrants the further investigation of opioid antagonism in the
service of therapy. Certainly, many difficulties are present; at least one-hour absorption
time would be required, and this problem alone might make its use impractical for
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general clinic use. Also, the potential negative side-effects of the drug (general malaise)
which might be exaggerated in the hypertensive-repressor, might reduce adherence to the
drug schedule or to the therapy in general. Clients would not be able to consume alcohol
for some time afterwards and some chronic pain conditions may worsen. Before acute
administration of naltrexone can be recommended, therefore, careful study of its pros and
cons in the therapeutic session would have to be carried out.
The development of hypertension

In the United States alone, more than 50 million people are estimated to have
chronically high blood pressure levels. Thirty-eight percent of blacks and twenty-nine
percent of whites have the condition (Merck Manual, 1997). Hypertension, as the leading
cause of stroke and a major cause of cardiovascular disease, is one of the most dangerous
conditions in the industrialized world. The causes of essential hypertension, which makes
up about 90% of hypertensive cases, are unknown. While several risk factors (e.g., family
history, obesity) are known, these factors alone are insufficient to explain the
development of hypertension.
The opioid-peptide theory holds that hypertension may be a learned response to
stressful stimuli (Dworkin et al., 1979). If increased blood pressure levels can produce
antinociceptive effects through baroreceptor-medicated, endogenous opioid activity,
heightened blood pressure levels can possibly become a conditioned response.
Essentially, elevations in blood pressure provide psychophysiological relief from stressful
situations, thus serving as a negative reinforcer for high blood pressure responses
(Randich & Maixner, 1984). Some individuals may be particularly susceptible to this
response, either because of a hypersensitive cardiovascular system (larger blood pressure
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responses) or hypersensitive antinociceptive/analgesic systems (Droste et al., 1994).
Furthermore, frequent exposure to stressors (i.e., highly stressful environments) may
more often trigger blood pressure and antinociceptive responses. Repeated experiences
with this cardiovascular-baroreceptor-opioid system may result in an instrumentally
conditioned, heightened blood pressure response to stressors. Over time, continual
reinforcement of elevated blood pressure levels may result in sustained hypertensive
conditions. In other words, hypertension may be an operantly conditioned response to
repeated exposure to stressors. This hypothesis of learned hypertension is supported by
research showing that heart rate and blood pressure can be operant!y conditioned in
nonhuman primates (Engel & Joseph, 1982; Mitchell, Graham, & Castracane, 1982).
Such a model would have important implications for the prevention and treatment
of hypertension. While no direct evidence of opioid-based treatment of hypertension is
available, it is possible that both opioid agonism and antagonism could prevent the
development of the disease. The inhibition of opioid systems may remove the reinforcer
of blood pressure increases. However, research has also found that opioid agonism, such
as the chronic administration of spiradoline (a nonpeptide kappa agonist) in rats, may also
prevent the development of hypertension (Wright & Ingenito, 200 1). In their study,
hypertension-prone rats were put into a socially isolated environment, a known anxiety
and stress producer. Nontreated rats developed hypertension in the stressful environment
while those treated with spiradoline did not. This treatment may work either by
minimizing experienced stress and thus preventing large blood pressure increases or by
creating a chronically elevated opioid environment in which larger spikes of opioid
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activation are impossible. In both cases, the reinforcer is removed, thus preventing
learned conditions of hypertension.
The susceptible individual

A number of factors may predispose an individual to comorbid hypertension
repression conditions. Cognitive threat assessment leads to sympathetic activation which
increases blood pressure, activating baroreceptors which cause the release of endogenous
opioids. At any point in this process, a hypersensitive system could create the possibility
of learned hypertension. An individual may be predisposed to interpret situations as
threatening. Personality types that are associated with hypersensitive threat assessment
may play a role here. The cardiovascular system itself may be excessively reactive.
Cardiovascular reactivity is already considered to be a risk factor for hypertension (Gerin
et al., 2000). A meta-analytic review of hypertension and cardiovascular reactivity to
acute stressors concluded that hypertensives usually exhibit larger blood pressure
responses to laboratory stressors and take longer to recover from those stressors
(Fredrikson & Matthews, 1990). Certainly, if hypertension is a learned response to
stressful situations, those individuals exhibiting the most variability in blood pressure and
the· greatest reactivity to stressors would be the ones most likely to experience
hypertension as a conditioned response.
Likewise, baroreceptor sensitivity may vary in individuals. Similar to a labile
cardiovascular system, a sensitive baroreceptor system would likely produce more
pronounced endogenous opioid effects and thus increase the chances of a conditioned
cardiovascular response. Baroreceptor reactivity has already been implicated as a
possible risk factor for hypertension (Ditto & Blaine, 1990).
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Environmental factors and experience with repeated stressors is another
consideration. While reactivity may be an individual trait contributing to hypertension, it
would also be important for an environment to provide sufficient stressors for such
learning to occur, indicating that environmental factors would play an important role in
the development of hypertension (Manuck et al., 1993). Development of hypertension
and the repressive coping style may result from interactions between susceptible
individuals and aggravating environments. Indeed, research has suggested that some
importance differences are found only when critical person/situation interactions are
introduced, such as the presence of a harassing confederate during an anagram task
performed by individuals scoring high in hostility (Saurez & William, 1989) or high
versus low control conditions presented to borderline hypertensives (Bohlin et al., 1986).
Therefore, hypertension as a conditioned stress response may only occur when a
vulnerable individual is placed in a stressful environment.
Limitations

Although the present study employed a strong experimental design for detecting
effects of naltrexone administration, several factors potentially limited effect sizes
observed in the present study. These factors will now be discussed.
Subclinical hypertension levels

The strength of between-group main effects and interaction effects may have been
reduced by the use of relatively healthy college students for the study sample. Instead of
using truly hypertensive sample, the study used high and low levels of a normotensive
range. While the two groups were truly distinct in their blood pressure levels, differences
may have been even greater if a clinically hypertensive sample was used. Previous
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studies observing a comorbid hypertension/repression phenomenon have consisted of
individuals with greater elevations of blood pressure than those used in the present study
(e.g., Winkleby, Ragland, & Syme, 1 988; Sapira, Scheib, Moriarty, & Shapiro, 1 97 1 ).
Future studies may make use of individuals with clinically elevated blood pressure, rather
than just high normotensives. Despite the problem of using a range of normotensives,
previous studies employing this design with experience of pain have produced significant
results, suggesting that the effect is measurable, but perhaps limited, in a normotensive
sample (Breuhl, Carlson & McCubbin, 1992).
Subclinical repression levels
Likewise, the strength of the present study may have been reduced by the use of
subclinical repressive individuals. Just as antidepressants are unlikely to produce large
changes in nondepressed individuals, we are unlikely to see the "treatment" naltrexone to
have any significant effect on normal levels of repression. If the drug were administered
to those presenting with pathologically high levels of repression, a stronger effect might
be observed. Future studies investigat�ng the role of endogenous opioids in repressive
coping might make use of clinically repressed individuals.
Small sample size
While the sample size used in the present study was adequate for within-subjects
tests, there was little power for testing between-groups effects. Although hypotheses
involving within-subjects variables were supported, group differences were not found in
most cases. These differences may reach significance with a larger sample size.
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Effect of repeated measures
The present study employed four identical sessions to measure within-subjects
effects. While this provides maximum control over potentially confounding factors, it
produces another problem: autocorrelation. Autocorrelation has the potential to inflate
and deflate statistical differences; however, in the present design, the effect was more
likely to reduce variability between sessions. As subjects completed the exact same set of
questionnaires in each session, there is the likelihood that responses in later sessions may
be more influenced by responses in previous sessions than in present mood. While the
scales in the packets were in different orders in each session, the "momentum" produced
by previous completions of the scales may carry through future sessions, and produce
similar responses. At least one participant claimed that he had "memorized" the
responses by the fourth session. The temporal proximity of the sessions may have
exaggerated this effect. Forty-eight hours was the minimum time allowed between
sessions. This time was chosen to allow for adequate elimination of the active drug
(complete elimination is usually achieved by 24 hours); however, responses to a scale
might be remembered over a two-day period. Although participants were encouraged to
"answer each item as honestly as possible," and to "answer the items as they feel now,"
there is no guarantee that individuals did not use schemata set by the first session to
answer scales in subsequent sessions. Alternatives, such as using different measures for
each session, or less objective measures, would present other flaws in the design. Future
studies may minimize the effect of repeated measures by increasing the time between
sessions and using only two sessions (rather than the four in the present design).
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Acute administration of the active pharmaceutical
While the mechanisms that might lead endogenous opioid antagonism to affect
cognitive events such as repression are unknown, it is possible that these mechanisms are
not easily engaged in an acute fashion. Where complex cognitive styles, defenses, and
coping mechanisms are involved, some time may be required before these systems
"reorganize" themselves around the new physiological "environment. " To return to the
anti-depressive metaphor, it is unlikely that an anti-depressive medication would have an
effect with one administration. Usually, sustained administration over a long period of
time is required before changes in mood and cognitive styles can be observed. A coping
strategy that has been developed over years may be initially resistant to any physiological
change; therefore, results achieved with an acute administration of a drug may be
minimized. In regard to endogenous opioid activity and repression, large changes in
coping style might be observed only with daily administration of the naltrexone. Several
factors make this design difficult however, such as low adherence (especially considerin_g
the potential negative side-effects) and the low but possible chance of liver damage (in
susceptible individuals). While long-term administration may produce theoretically
interesting changes, there is little feasibility in using naltrexone as a sustained treatment
for repression. The practical usefulness of naltrexone lies in its ability to produce acute
changes in repressive symptoms. However, if hypertension precedes repression, direct
treatment of the hypertension may be a more promising route of treatment. As evidenced
by the systolic increases in the present study, treating repression without treating
hypertension may lead to even higher increases in blood pressure.
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Short administration-to-measurement interval
In a similar way, the short amount of time between administration of naltrexone
and measurement of dependent variables may have contributed to the small observed
effects. While peak plasma absorption is usually achieved by one hour (Meyer, Straughn,
Lo, Schary, & Whitney, 1984), it is unknown whether this is adequate time for cognitive
effects to occur. Absorption time may vary by individual and is likely impacted by
factors such as prior food consumption. Since naltrexone's potential impact on cognitive
functions have never been assessed, it in unknown by what exact mechanisms the change
occurs and how long it takes for this change. While the present study certainly shows
significant effects after one hour, it is possible that a longer administration-measurement
interval would yield larger results. As evidence for this possibility, participants were
asked to guess whether they have received the active drug or the placebo. Several
participants who responded "placebo" later returned and said they wanted to change their
original guess to "drug," as effects surfaced later in the day after the session has ended.
Of the four times this occurred, the newer guess of "drug" was always correct. This
suggests that significant experienced effects of the drug may not manifest until some time
has passed. While this possibility was noted prior to the running of the study, alternatives
were determined to be too problematic to be helpful. Scheduling problems and adherence
problems would have been greatly increased by requiring participants to stay, for
example, two hours while the drug is absorbed. Furthermore, due to possible serious side
effects (such as anaphylactic shock) which usually manifest in the first hour, it was
considered unsafe to allow participants to consume the drug and then return later for
measurement. In cases where human subjects are used, participant safety is paramount to
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design concerns and proper safety would require monitoring during the administration
period.
Incomplete antagonism of opioid and non-opioid systems
While naltrexone is an extremely effective opioid antagonist, its affinity is
roughly 1 0 times greater for mu receptors than kappa receptors (Preston & Bigelow,
1 992; Martin, 1 984). Therefore, kappa-mediated effects may still be expressed despite
complete blockage of mu effects. Some parts of the opioid-analgesic system may still be
operating in the presence of naltrexone, which would further serve to diminish observed
differences between the drug and placebo. While the mu receptors seem important in the
role of analgesia of physical pain, it is not known how the receptors differentially mediate
the cognitive effects of opioids in regard to repression. There is evidence, however, that
kappa antagonism actually increases dysphoric effects (see Schlaepfer, Stain, Greenberg,
Preston, & Lancaster, 1 998), suggesting kappa antagonism may not further diminish
repressive phenomena. Study of kappa antagonism and its effect on pain and repression is
greatly hindered by the lack of kappa antagonists although it is generally thought that
kappa activity is unrelated to euphoria (Julien, 1 992).
Furthermore, research in hypertension/repression mechanisms is complicated by
the existence of non-opioid intrinsic analgesic systems (Terman, Shavit, & Lewis, 1 984).
The existence of pain systems other than opioid-mediated ones is supported by research
showing that some forms of analgesia can be reliably blocked with naloxone while others
cannot (Cannon et al., 1 982) and that the relationship between blood pressure and pain
perception is not always moderated by the introduction of naloxone (McCubbin &
Bruehl, 1 994). Both systems of analgesia (opioid and non-opioid) have been selectively
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activated by varying, with rats, shock temporal patterns (Lewis, Cannon, and Liebeskind,
1980), body region of the shock (Watkins & Mayer, 1982) and escapability of the shock
(Moye et al., 1983). While the mechanisms involved in the non-opioid system(s) are not
clear, there are suggestions that histamine (Terman, Shavit, & Lewis, 1984; Terman,
Lewis, & Liebeskind, 1982; Lewis, Terman, Nelson, & Liebeskind, 1984), serotonin, or
vasopressin (Randich and Maixner, 1984), may play a role.
If the inhibition of pain is a complicated collection of multiple opioid and non
opioid systems, it is most likely that mechanisms for cognitively-experienced stress is
just as complicated. Therefore, the selective opioid antagonist naltrexone may only
hinder part of this system. Larger effects on repressive phenomena may be observed
when multiple routes of antinociception/analgesia are manipulated.
Conclusion
Taken together, the results of the present study make a convincing argument for
the role of endogenous opioids in hypertension and repression. While certainly
exploratory in nature, it provides initial evidence that endogenous opioids may have
much more important implications to humans than just analgesia. Endogenous opioids
may indeed play a critical role in both the development of repression and hypertension.
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FIGURE A- 1: Group differences in a) SBP and b) DBP in the cardiovascular status
confirmation (validation)

76

TABLE A- 1 : SBP and DBP for participants in the initial screening and confirmation
a) Initial Screening
Subject

b) Confirmation

SBP

DBP

SBP

DBP

1 08
102
95
98
1 03
98
99
107

52
55
58
56
59
53
49
57

1 07
1 04
1 02
1 06
98
111
95
109

63
57
55
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62
58
60
49

1 35
1 35
1 42
1 46
1 39
1 40
141
1 35
140
1 32
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60
53
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69
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141
131
1 33
1 46
1 39
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71
68

Low pressure group
2
3
6
8
13
14
16
17
High pressure group
1
4
5
7
9
10
11
12
15
18
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FIGURE A-2: Effect of drug on POMS tension responding for both hypertensives and
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FIGURE A-3 : Effect of drug on life concerns for hypertensives and normotensives
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FIGURE A-4: Repressive coping as measured by the ISE for hypertensives and
normotensives in the drug versus placebo conditions
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a) without inhibition of opioid systems:
opioid activity moderates the relationship between objective stressor and subjective stress
by attenuating cognitive appraisal of threat
opioid activation
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heightened SBP

b) with inhibition of opioid systems:
naltrexone blocks the inhibitory effects of opioids ; therefore, blood pressure levels rise
uninhibited. ..
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FIGURE A-7 : Endogenous opioid feedback loop (a) normal and (b) disrupted with
naltrexone
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